Navigation Links
Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Date:10/1/2009

PARIS, Oct. 1 /PRNewswire/ -- Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. The deal is valued to a total of euro 370M, including an immediate upfront payment and subsequent milestone payments related to the progress of the clinical compounds. The closing of the transaction is expected to occur in the 4th quarter of 2009.

Fovea was created in 2005 by Professeur Jose A. Sahel, Bernard Gilly and Pierre Belichard, with the initial seeding of Sofinnova Partners in Paris. It successfully raised two rounds of funding in November 2005 and February 2008, from a syndicate of pan-european investors including Sofinnova Partners, Abingworth Management, Forbion Capital Partners, The Wellcome Trust, GIMV, Credit Agricole Private Equity and Vesalius BioCapital.

Fovea has rapidly built a pipeline of products: FOV 1101, an eye drop, fixed dose combination of prednisolone and cyclosporine, currently in phase II for the treatment of persistent allergic conjunctivitis, FOV 2302, an intravitreal formulation of a plasma kallikrein inhibitor, in phase I for the treatment of Retinal Vein Occlusion induced macular edema and FOV 2304, a potent antagonist of bradykinin B1 receptor, active by eye drop, scheduled to enter in phase I by November 2009 for the treatment of diabetic macular oedema.

"Our team is proud and extremely pleased to join sanofi-aventis, as it will provide the necessary resources and expertise needed to continue to aggressively build the ophthalmology franchise and demonstrate the efficacy of our products through regulatory clinical development," commented Bernard Gilly, President and Chief Executive Officer of Fovea Pharmaceuticals. "It also demonstrates that strong science combi
'/>"/>

SOURCE Fovea Pharmaceuticals SA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
2. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
3. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
4. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
5. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
6. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
8. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
9. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... June 18, 2013 Valeant Pharmaceuticals International, Inc. ... priced its previously announced public offering of common shares ... issue 23,529,412 common shares at a price of $85.00 ... billion. The Company will file a final prospectus supplement ... and will make a similar filing with the securities ...
(Date:6/18/2013)... ROCKY HILL, Conn. , June 18, 2013 ... many past clients of Alliance Seating and Mobility, ... now unable to access timely repair. This appears ... and a dramatic reduction of field service employees.  ... Unfortunately a great many of these clients ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... Calif., Aug. 31, 2011 Onyx Pharmaceuticals, ... it has appointed Helen Torley, M.B. Ch. B., M.R.C.P., ... her role, Dr. Torley will report to N. Anthony ... be responsible for all commercial activities related to Nexavar ...
... MOUNTAIN VIEW, Calif., Aug. 31, 2011 Concentric Medical, ... today announced that Stryker Corporation (NYSE: SYK ... Medical for $135 million in an all-cash transaction. The ... early in the fourth quarter of 2011. ...
Cached Medicine Technology:Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3STRYKER Signs Definitive Agreement to Acquire CONCENTRIC MEDICAL, Inc. 2
(Date:6/19/2013)... 2013 North American Seminars combines ... course with an online continuing education course ... occupational therapists. , The two day ... an online continuing education course will ... solving skills needed to evaluate and treat dizziness ...
(Date:6/19/2013)... MA (PRWEB) June 19, 2013 ... collaboration and sensor machine software, today announced it ... for its Decentralized Fusion Engine technology. The ... and the acquisition of key strategic partnerships. ... and wireless collaboration and machine-to-machine (M2M) software products ...
(Date:6/19/2013)... Francisco, CA (PRWEB) June 19, 2013 The ... sized tents is because users can place a 4x8 flood ... clearance boundary space to work around. In addition, Gorilla ... tents. Because they are the tallest, thickest and strongest grow ... new bar for grow tent standards. , Gorilla ...
(Date:6/19/2013)... Tornadoes and their devastating aftermath have increased across the ... to these deadly storms find it hard to recover. ... and corporations from natural and man-made disasters for over ... philosophy of providing a storm shelter that can be ... stand up, with light and a battery-operated blower for ...
(Date:6/19/2013)... DC (PRWEB) June 19, 2013 ... in the history of managed care. As many ... coverage through the new state-based and federally operated ... for essential health benefits, and examples of premium ... states, industry-leading health business information publisher Atlantic Information ...
Breaking Medicine News(10 mins):Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2Health News:Blueforce Awarded Patent for Decentralized Sensor Fusion 2Health News:Stealth Grow Tent Brand’s Popularity Rises 2Health News:Radius Engineering International Inc. Tornado-Resistant Storm Shelters 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2
... could help many avoid stroke , , THURSDAY, Jan. 24 (HealthDay ... for preventing strokes was stopped early because of excess bleeding, ... researchers said the trial could open the way to at ... seems to occur primarily in two groups of people -- ...
... Preserve Competition in Three Clinical Testing,Markets, WASHINGTON, ... that it will require Pearson Plc to divest ... to proceed with,Pearson,s proposed $950 million acquisition of ... originally proposed, would have,resulted in higher prices to ...
... of,Health and Human Services (HHS) Secretary Mike ... developed by the Healthcare Information,Technology Standards Panel ... three,of its "Interoperability Specifications" to help support ... Nationwide Health Information Network in,the United States ...
... disease ulcerative colitis are at increased risk of developing ... colleagues at Kanazawa University, Japan, identified a central role ... colon cancer in mice in which inflammation of the ... by repeated dextran sulfate sodium (DSS) ingestion. Expression of ...
... The U.S. Department of,Labor today announced a $1,250,000 ... to help provide assistance in paying health insurance,premiums ... for the,Health Coverage Tax Credit. The assistance is ... of 2002., "This $1.25 million grant will ...
... SCOTTSDALE, Ariz., Jan. 24 DC Ranch Village ... literally. The latest yoga class,Chocolate-Covered Yoga, teaches yogis how ... but also how to heighten the senses, and experience,sensations ... eating., The class is a very fulfilling yoga ...
Cached Medicine News:Health News:Anti-Clotting Drug Trial Shortened by Bleeding Problems 2Health News:Justice Department Requires Divestitures in Pearson's Acquisition of Harcourt Assessment 2Health News:Justice Department Requires Divestitures in Pearson's Acquisition of Harcourt Assessment 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4Health News:U.S. Department of Labor Announces $1.25 Million to North Carolina to Help Trade-Affected Workers Pay for Health Insurance 2Health News:DC Ranch Village Health Club & Spa Twists with Chocolate Yoga Class 2
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in...
... Xact stent is self-expanding and has a closed-cell ... flexible mesh intended to help restore the inner ... inner vessel surface, and potentially reduce the release ... when it is treated, which can lead to ...
... With BareWire technology, the wire crosses the ... delivery catheter. All other actions, including filter ... placement then occur over the wire., ,Emboshield ... break off during a carotid stenting procedure, ...
Medicine Products: